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ed February 25, 2014.he authors propose simultaneous inhibition of Gbg signaling in the heart and the adrenal gland as a novel
therapeutic approach for heart failure (HF).Background Elevated sympathetic nervous system activity is a salient characteristic of HF progression. It causes pathologic
desensitization of b-adrenergic receptors (b-AR), facilitated predominantly through Gbg-mediated signaling. The
adrenal glands are key contributors to the chronically elevated plasma catecholamine levels observed in HF,
where adrenal a2-AR feedback inhibitory function is impaired also through Gbg-mediated signaling.Methods We investigated the efﬁcacy of a small molecule Gbg inhibitor, gallein, in a clinically relevant, pressure-overload
model of HF.Results Daily gallein treatment (10 mg/kg/day), initiated 4 weeks after transverse aortic constriction, improved survival and
cardiac function and attenuated cardiac remodeling. Mechanistically, gallein restored b-AR membrane density in
cardiomyocytes, attenuated Gbg-mediated G-protein–coupled receptor kinase 2–phosphoinositide 3-kinase g
membrane recruitment, and reduced Akt (protein kinase B) and glycogen synthase kinase 3b phosphorylation. Gallein
also reduced circulating plasma catecholamine levels and catecholamine production in isolated mouse adrenal
glands by restoring adrenal a2-AR feedback inhibition. In human adrenal endocrine tumors (pheochromocytoma),
gallein attenuated catecholamine secretion, as well as G-protein–coupled receptor kinase 2 expression and
membrane translocation.Conclusions These data suggest small molecule Gbg inhibition as a systemic pharmacologic therapy for HF by simultaneously
normalizing pathologic adrenergic/Gbg signaling in both the heart and the adrenal gland. Our data also suggest
important endocrine/cardiovascular interactions and a possible role for small molecule Gbg inhibition in treating
endocrine tumors such as pheochromocytoma, in addition to HF. (J Am Coll Cardiol 2014;63:2549–57)
ª 2014 by the American College of Cardiology FoundationHeart failure (HF) is a progressive disease with poor prog-
nosis. A common feature of HF is elevated sympathetic
nervous system activity to compensate for poor cardiac
output, including excess adrenal production of the cate-
cholamines (CA) epinephrine and norepinephrine (1–3).
Chronic CA-mediated stimulation of b-adrenergic receptorsChildren’s Hospital Medical Center, Cincinnati,
nstitute, Department of Medicine, University of
ew York; zDepartment of Surgery, University of
New York; xDepartment of Medicine, University
r, New York; and the kDepartment of Pharma-
ochester Medical Center, Rochester, New York.
1 HL089885 and NIH R01 HL091475 (to
ral fellowship (to Dr. Kamal). The authors have
relevant to the contents of this paper to disclose.
2013; revised manuscript received February 10,(b-AR, a G-protein–coupled receptor [GPCR]), elicits
pathologic upregulation of G-protein–coupled receptor ki-
nase 2 (GRK2) that is recruited to membrane Gbg subunits
to phosphorylate b-AR, leading to their desensitization
(4,5). Prior reports suggest a therapeutic role for inhibiting
the Gbg–GRK2 interaction in HF to restore b-AR
expression and function, utilizing a truncated Gbg-binding
GRK2 peptide that lacks the kinase domain (bARKct) (6–13),
as well as a truncated Gbg-binding phosducin (14) and a
truncated phosphoinositide 3-kinase g (PI3Kg) (15–17).See page 2558Interestingly, Gbg–GRK2 was recently found to desensitize
the adrenal a2-AR, another GPCR responsible for feedback
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2550inhibition of CA release from the
adrenal gland. Importantly, adre-
nal a2-AR desensitization con-
tributes to elevated plasmaCAand
consequent b-AR desensitization
in HF (18,19).
We recently identiﬁed and
validated novel compounds that
selectively inhibit Gbg binding
interactions (20), namely, M119
and its highly homologous struc-
tural analog, gallein. These com-
pounds competitively antagonize
the binding of GRK2 to a spe-
ciﬁc protein–protein interaction
domain of the Gbg subunit, thus
inhibiting the pathologic Gbg–GRK2 interaction. Both compounds bind to Gbg with equal
afﬁnity in vitro, and have equivalent efﬁcacies in enhancing
contractility in isolated cardiomyocytes as well as in acute
pharmacologic and genetic mouse models of HF (21). The
advantages of these compounds include their convenient
route of administration (intraperitoneal injection or oral
gavage), bioavailability, and cell permeability (22). Addi-
tionally, they inhibit the Gbg–GRK2 interaction without
disturbing various other aspects of basal or agonist-stimulated
G-protein signaling (20). We were the ﬁrst to report earlyfﬁcacy of Gallein After Transverse Aortic C
e experimental timeline showing initiation of gallein tr
t cardioprotective effect of daily intraperitoneal (i.p.)
function (echocardiography, % fractional shortening).
-way analysis of variance and Bonferroni’s post-hoc a
(using repeated measures analysis of variance with B
se aortic constriction plus vehicle.proof-of-concept studies regarding possible beneﬁcial effects
of these newly identiﬁed compounds in acute pharmaco-
logical and transgenic animal models of HF (21).
In the present study, we report the therapeutic efﬁcacy of
the selective small molecule Gbg inhibitor, gallein, when
delivered after the establishment of HF in a clinically relevant
surgicalmodel. Further, we report concomitant salutary effects
of gallein on the adrenal gland, including direct inhibition
of adrenal CA synthesis and release both in HF animal
models and in primary human adrenal pheochromocytoma
tissue. We propose that simultaneous small molecule inhibi-
tion of Gbg signaling in the heart and in the adrenal gland is a
novel therapeutic approach for HF, and possibly for other
diseases of excess CA release, such as pheochromocytoma.Methods
Detailed materials and methods are included in the Online
Appendix.Results
The small molecule Gbg inhibitor gallein dose-
dependently ameliorates cardiac dysfunction and hyper-
trophy in HF mice. To test the possible therapeutic effects
of small molecule Gbg inhibition in treating established
HF, daily gallein administration was initiated 4 weeks afteronstriction
eatment after the establishment of heart failure, i.e., 4 weeks after transverse aortic
gallein (G) was observed by both (B) cardiac morphometry (ventricular weight to
Optimal therapeutic dose was 10 mg/kg/day. ###p < 0.001 vs. sham; **p < 0.01
nalysis); xp < 0.05 vs. baseline TACþV; VVp < 0.01 vs. all groups at baseline;
onferroni’s post-hoc analysis). TACþG ¼ transverse aortic constriction plus gallein
Figure 2 Salutary Effect of Gallein Post-Transverse Aortic Constriction
(A) Gallein (G; 10 mg/kg/day)-treated mice showed enhanced survival (80%; 8 of 10), whereas mice receiving vehicle injection (V) showed lower survival rate (54.55%; 6 of 11)
relative to 100% survival in the sham group. (B) Cardiac b-adrenergic receptor (b-AR) density was signiﬁcantly reduced in transverse aortic constriction (TAC) mice and was
recovered to almost normal levels by gallein treatment. (C) G-protein–coupled receptor kinase 2 (GRK2) gene expression was elevated in TACþV mice and was reduced by
gallein treatment. (D) M-mode echocardiographic images showing impaired contractile function in TACþV group and recovered function in gallein-treated animals. This likely
resulted from gallein-mediated recovery of b-AR function due to attenuation of GRK2 and phosphoinositide 3-kinase g (PI3Kg) membrane recruitment (E and F). *p < 0.05 vs.
sham; yp < 0.001, zp < 0.01, and xp < 0.05 vs. TACþV (using 1-way analysis of variance with Bonferroni’s post-hoc analysis). Nonparametric analysis of b-AR binding utilizing
Kruskal Wallis test yielded p < 0.05 for sham vs. TACþV. GAPDH ¼ glyceraldehyde 3-phosphate dehydrogenase.
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2551transverse aortic constriction (TAC) and continued for 8
weeks (12 weeks post-TAC). Gallein dose-dependently
reduced ventricular hypertrophy (deﬁned as the ratio of
ventricular weight to tibia length) and improved cardiac
function (Fig. 1, Online Fig. 1). Administration of gallein at
a dose of 10 mg/kg/day was found to be the optimal ther-
apeutic dose, and was thus utilized for subsequent studies
(identiﬁed as TACþG).Table 1 Echocardiographic Measurements of Mice at Baseline and W
Baseline 4 Weeks
TACþV TACþG TACþV TACþG
%EF 80.42  2.01 81.97  0.51 70.4  5.04 74.08  2.4
%FS 50.91  0.68 49.37  0.51 39.90  4.04 42.26  2.0
LVIDs (mm) 1.50  0.07 1.54  0.06 1.92  .25 1.92  0.1
LVIDd (mm) 3.16  0.08 3.06  0.09 3.44  0.23 3.37  0.1
Systolic
volume (ml)
7.20  0.44 6.83  0.55 16.22  4.56 12.31  2.0
Diastolic
volume (ml)
39.76  1.99 37.62  2.37 50.17  7.21 46.09  3.9
*p < 0.01 vs. baseline TACþV (using repeated measures analysis of variance and Bonferroni’s post
of variance and Bonferroni’s post-hoc analysis). zp < 0.05 vs. baseline TACþV (using repeated measures
(using repeated measures analysis of variance and Bonferroni’s post-hoc analysis).
EF ¼ ejection fraction; FS ¼ fractional shortening; LVIDd ¼ left ventricular internal diameter diastolic; LV
TACþV ¼ transverse aortic constriction plus vehicle.Gallein improves survival and preserves cardiac con-
tractility in pressure overload hypertrophy. After 8 weeks
of daily treatments initiated 4 weeks post-TAC (i.e., at 12
weeks post-TAC), gallein signiﬁcantly enhanced survival to
80%, compared with 54% survival in the vehicle treated
group TACþV (Fig. 2A). Cardiac function in TACþV
mice declined at 8 weeks post-TAC, with further deteri-
oration at week 12. Gallein treatment initiated aftereeks 4, 8, and 12 Post-TAC
8 Weeks 12 Weeks
TACþV TACþG TACþV TACþG
8 58.40  9.29 73.82  2.29 51.26  9.84* 75.77  3.47y
0 32.16  6.07z 41.94  1.88 26.14  5.28* 44.08  2.81x
4 2.55  0.52 1.91  0.13 2.94  0.71 1.80  0.13x
3 4.04  0.37 3.25  0.12 4.41  0.58z 3.25  0.12y
2 38.65  15.69 11.57  1.98 62.34  28.75z 11.19  2.38x
7 74.64  16.87 42.77  3.60 98.08  30.08z 43.88  3.61x
-hoc analysis). yp < 0.05 vs. TACþV at 12 weeks post-TAC (using repeated measures analysis
analysis of variance and Bonferroni’s post-hoc analysis). xp < 0.01 vs. TACþV at 12 weeks post-TAC
IDs ¼ left ventricular internal diameter systolic; TACþG ¼ transverse aortic constriction plus gallein;
Table 2 Hemodynamic Measurements of Sham, TACþV, and TACþG Mice at End of Study
Sham TACþV TACþG
LVEDP (mm Hg) 6.73  1.83 23.94  4.91* 8.57  2.15y
þdP/dt (mm Hg/s) 8777  860.3 5249  913.3z 8677  743.0y
-dP/dt (mm Hg/s) 8027  926.5 4022  570.6z 7792  824.9y
LV min (mm Hg) 4.99  1.31 18.32  5.03z 5.92  2.33y
LV max (mm Hg) 129.3  3.98 109.9  14.57 166.4  13.35y
*p < 0.01 vs. sham (using 1-way analysis of variance and Bonferroni’s post-hoc analysis). yp < 0.05 vs. TACþV (using 1-way analysis of variance and
Bonferroni’s post-hoc analysis). zp < 0.05 vs. sham (using 1-way analysis of variance and Bonferroni’s post-hoc analysis).
dP/dt ¼ ﬁrst derivative of left ventricular pressure; LV max ¼maximal left ventricular pressure; LV min ¼ minimal left ventricular pressure; LVEDP¼
left ventricular end-diastolic pressure; TACþG ¼ transverse aortic constriction plus gallein; TACþV ¼ transverse aortic constriction plus vehicle.
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2552establishment of HF prevented such deterioration and
preserved cardiac function (Tables 1 and 2, Fig. 2D).
Gallein restores b-AR density, down-regulates GRK2
expression, and inhibits GRK2 and PI3Kg membrane
recruitment. To evaluate mechanisms underlying the
beneﬁcial effects of gallein on cardiac function, we measured
b-AR density, GRK2 and PI3Kg membrane recruitment,Figure 3 Gallein Reduces Ventricular Hypertrophy and Akt Phosphor
(A) Hypertrophy (ventricular weight to tibia length, VW/TL) was attenuated in gallein-treat
cross-sectional area (CM CA) in gallein-treated mice as a quantiﬁcation of (C) wheat germ
bar ¼ 50 mm). (D) Reduced cytosolic Ser473-Akt phosphorylation as compared with total
protein expression in gallein-treated mice (densitometric analysis and fold change), in par
xp < 0.05, kp < 0.01, and {p < 0.001 vs. TACþV (using 1-way analysis of variance with B
Wallis test yielded p < 0.05 for sham and p < 0.01 for TACþG vs. TACþV.and GRK2 gene expression. TAC mice exhibited a signiﬁ-
cant reduction in b-AR density that was normalized by
gallein treatment (Fig. 2B). This was accompanied by
a reduction in cardiac GRK2 gene expression and
GRK2-PI3K110g membrane translocation in TACþG
mice compared with TACþV mice (Figs. 2C, 2E, and 2F,
respectively).ylation Post-Transverse Aortic Constriction
ed (G) post-transverse aortic constriction (TAC) animals. (B) Reduced cardiomyocyte
agglutinin staining (WGA, green; nuclear 40,6-diamidino-2-phenylindole, blue; scale
Akt protein expression, and (E) Ser9-GSK-3b phosphorylation relative to total GSK-3b
allel with VW/TL and CM CA data. *p < 0.001, yp < 0.01, and zp < 0.05 vs. sham;
onferroni’s post-hoc analysis). Nonparametric analysis of pGSK/GSK utilizing Kruskal-
Figure 4 Reduced Cardiac Fibrosis and Inﬂammatory Markers in Gallein-Treated Mice Post-Transverse Aortic Constriction
(A) Picrosirius red and (B) Masson’s trichrome staining shows less cardiac ﬁbrosis in gallein-treated mice after transverse aortic constriction (TACþG) than in vehicle-treated
mice (TACþV). (C to H) Real time polymerase chain reaction analysis of inﬂammatory and proﬁbrotic gene expression (normalized to glyceraldehyde 3-phosphate dehydrogenase
[GAPDH] as housekeeping gene) in cardiac RNA extracts show attenuated gene expression of these markers by gallein treatment. *p < 0.001, yp < 0.01, and zp < 0.05 vs.
sham; xp < 0.001 and kp < 0.05 vs. TACþV (using 1-way analysis of variance with Bonferroni’s post-hoc analysis). Nonparametric analysis of Nppb and Il6 utilizing Kruskal-
Wallis test yielded p < 0.05 for sham vs. TACþV and p < 0.01 for TACþG vs. TACþV, respectively. Acta2 ¼ actin a2; Il1b ¼ interleukin 1b; Il6 ¼ interleukin 6; Nppa ¼ atrial
natriuretic peptide; Nppb ¼ brain natriuretic peptide; TNFa ¼ tumor necrosis factor-a.
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2553Gallein attenuates cardiac remodeling and inﬂammation
in pressure overload HF. Gallein treatment attenuated the
progressionof cardiac hypertrophy inTACmice, as reﬂected by
reduced ventricular weight to tibia length ratio (Fig. 3A) and
cardiomyocyte cross-sectional area (Figs. 3B and 3C). This
protective effect of gallein on cardiac hypertrophy was accom-
panied by reduced phosphorylation of cardiac Akt (also known
as protein kinase B) (Fig. 3D) and its downstream signal,
GSK-3b (Fig. 3E), and a parallel reduction in myocardial
ﬁbrosis (Figs. 4A and 4B). This may be attributed to the
signiﬁcantly reduced expression of the fetal genes atrial natri-
uretic peptide and brain natriuretic peptide (Figs. 4C and 4D),
the inﬂammatory cytokines interleukin 1b, interleukin 6, and
tumor necrosis factor-a (Figs. 4E to 4G), and the proﬁbrotic
marker a-smooth muscle actin (Fig. 4H). Moreover, we
observed less myocardial apoptosis in TACþG mice as evi-
denced by fewer apoptotic nuclei and reduced caspase-3
cleavage in cardiac lysates (Online Fig. 2).
Gallein attenuates CA production and adrenal remodeling
and restores adrenal a2-AR feedback inhibition in TAC
mice. Heart failure is associated with chronically ele-
vated plasma CA concentrations. At 12 weeks post-
TAC, gallein signiﬁcantly reduced plasma epinephrineand norepinephrine concentrations to 1.5-fold and 2.5-fold
of baseline, respectively, whereas vehicle-treated mice
showed signiﬁcant elevations of 2.8-fold and 7.5-fold,
respectively (Figs. 5A and 5B). Adrenal medulla hypertro-
phy is a common feature in HF that occurs concurrently
with elevated plasma CA levels (23); this was also reduced
by gallein treatment (Fig. 5C). Further, adrenal glands
from TACþG mice cultured in vitro showed signiﬁcantly
lower levels of basal CA secretion (Figs. 5D and 5E).
Adrenal a2-AR normally provides feedback inhibition of
excess CA release, a function that is desensitized in HF.
Gallein also restored a2-AR feedback inhibitory function
as compared with TACþV mice (Figs. 5F and 5G).
Further, gallein attenuated the overexpression of tyrosine
hydroxylase (rate-limiting enzyme of CA production) and
chromogranin A (neurokine that is synthesized, costored,
and cosecreted with vesicular CA) (Fig. 5C, Online Fig. 3).
Gallein directly restores a2-AR feedback inhibitory
function in adrenal glands from untreated isoproterenol-
pump mice. Ex vivo cultured adrenal glands from untreated
mice chronically exposed to the b-AR agonist isoproterenol
exhibit impaired adrenal a2-AR function, similar to other
HF models. Importantly, in vitro gallein treatment directly
Figure 5
Gallein Reduces Plasma Catecholamines and Adrenal Hypertrophy, and Restores Adrenal a2-AR Feedback Inhibition of
Catecholamine Release in HF Mice
(A and B) Gallein treatment in post-transverse aortic constriction mice (TACþG) reduces circulating plasma catecholamines (norepinephrine [NEpi], A; epinephrine [Epi], B)
compared with vehicle-treated mice (TACþV). (C) Gallein attenuates adrenal medullae hypertrophy post-TAC (hematoxylin-eosin staining of parafﬁn-ﬁxed adrenal sections; scale
bar ¼ 25 mm) and attenuates tyrosine hydroxylase (TH) as well as chromogranin A (CgA) protein expression in adrenal chromafﬁn cells (immunoﬂuorescent staining; scale bar ¼
50 mm). (D and E) Gallein reduces chronically elevated catecholamine secretion in ex vivo cultures of post-TAC adrenal medullae. (F and G) Adrenal a2-adrenergic receptor
(a2-AR) feedback inhibitory function is recovered by gallein treatment in TAC mice. *p < 0.0001, yp < 0.001, zp < 0.01, and xp < 0.05 vs. sham; kp < 0.01 and {p < 0.05 vs.
TACþV (using 1-way analysis of variance with Bonferroni’s post-hoc analysis). Nonparametric analysis of plasma epinephrine utilizing Kruskal-Wallis test yielded p < 0.001 for
sham vs. TACþV.
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2554restored the a2-AR feedback inhibitory function in these
adrenal glands (Online Fig. 4).
Gallein directly attenuates CA secretion and GRK2
protein expression and membrane translocation in
cultured human pheochromocytoma. Pheochromocytoma
is a tumor of the adrenal gland characterized by excessive
CA production (24). Gallein treatment signiﬁcantly reduced
CA production in cultured pheochromocytoma slices
(Figs. 6A and 6B) with attenuated GRK2 protein expression
and membrane translocation (Figs. 6D and 6E, respec-
tively). Interestingly, expression of tyrosine hydroxylase
and chromogranin A was signiﬁcantly down-regulated by
gallein treatment in cultured pheochromocytoma slices
(Fig. 6C). Further, a2-AR feedback inhibitory function
trended toward improvement in gallein-treated cultured
pheochromocytoma slices (Online Fig. 5).
Discussion
Small molecule Gbg inhibition halts HF progression
post-TAC. In the present study, we demonstrate the efﬁ-
cacy of the small molecule Gbg inhibitor, gallein, in
ameliorating establishedHF through simultaneous inhibitionof Gbg in the heart and the adrenal gland. Importantly,
gallein partially restores normal cardiac function and halts or
reverses pathologic cardiac remodeling when administered
after the establishment of chronic HF in a clinically relevant
animal model. It is noteworthy that gallein treatment in sham
animals mildly increases cardiac contractility as we have
previously shown (21) and in Online Figure 6.
We observed a dose-dependent therapeutic effect of gal-
lein on cardiac function and hypertrophy in TAC mice
in vivo, with 10mg/kg/day identiﬁed as the optimal dose.
Concomitantly, gallein treatment attenuated cardiac ﬁbrosis
and apoptosis, indicating attenuated cardiac remodeling.
Further, gallein treatment attenuated cardiac inﬂammatory
cytokine expression in TAC HF mice (Figs. 4E to 4G). Our
preliminary studies have demonstrated possible systemic
anti-inﬂammatory effects of Gbg inhibitors in a mouse
carrageenan-induced paw inﬂammation model (25). Prior
studies have correlated inﬂammation and loss of cardiac
function in pressure overload hypertrophy (26,27). Thus,
attenuated cardiac inﬂammation in TAC mice by gallein
may provide an additional mechanism for its therapeutic
effect in pressure overload HF.
Figure 7 Model for Dual Efﬁcacy of Small Molecule Gbg Inhibition in Heart and Adrenal Gland During HF
(A) In cardiomyocytes, Gbg–G-protein–coupled receptor kinase 2 (GRK2) interaction, triggered by elevated sympathetic nervous system (SNS) activity in heart failure (HF),
signals b-adrenergic receptor (b-AR) desensitization. (B) In adrenal chromafﬁn cells, the site of catecholamine (CA) production, 1) central nicotinic stimulation triggers, 2)
synthesis, and 3) secretion of CA into plasma. High levels of plasma CA, 4) stimulate a2-AR-mediated 5) feedback inhibition of CA synthesis and secretion. (C) In HF, continuous
CA stimulation of a2-AR triggers its Gbg-GRK2–mediated desensitization and the loss of feedback inhibition of CA release, contributing to SNS overactivity in HF. (D) Small
molecule Gbg inhibitors may provide a novel therapeutic approach for HF by inhibiting Gbg–GRK2 signaling simultaneously in the heart and the adrenal gland, thus breaking this
vicious cycle.
Figure 6 Gallein Reduces Catecholamine Secretion and Normalizes a2-AR Feedback Inhibition in Diseased Human Adrenal Medullae
Ex vivo cultured human adrenal pheochromocytoma slices were treated with gallein (G; 10 mmol/l) or vehicle (V) for 48 h. (A and B) Gallein treatment attenuates catecholamine
secretion (norepinephrine [NEpi], A; epinephrine [Epi], B). (C) Gallein attenuates tyrosine hydroxylase (TH) and chromogranin A (CgA) protein expression levels and (D and E)
attenuates G-protein–coupled receptor kinase 2 (GRK2) protein expression and membrane translocation (densitometric analysis and fold change; normalized to glyceraldehyde
3-phosphate dehydrogenase [GAPDH] or total protein content [by ponceau staining]). *p < 0.0001, yp < 0.001, zp < 0.01 vs. group V (using Student t test and nonparametric
utilizing Mann-Whitney U test).
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2556In summary, gallein increased survival, improved cardiac
function, and reduced cardiac remodeling and inﬂammation
when administered daily to mice with established HF, i.e., 4
weeks through 12 weeks post-TAC.
Small molecule Gbg inhibition preserves cardiac membrane
b-AR density by attenuating GRK2–PI3Kg signaling.
Excess sympathetic nervous system activity and outﬂow are
salient characteristics of HF, in which reduced cardiac output
triggers compensatory sympathetic nervous system overactivity
(elevated local and circulating CA) that acutely rescues cardiac
function. However, chronic stimulation of b-AR by CA leads
to their desensitization and attenuated contractile signaling
(1–3). Receptor desensitization is mainly mediated by the
Gbg subunits, which recruit receptor-desensitizing kinases
such as GRK2 and PI3Kg to agonist-stimulated b-AR,
resulting in receptor phosphorylation and the recruitment of
arrestins that initiate receptor internalization, desensitization,
and down-regulation (5,28–30). Previous data from our lab-
oratory and others suggest that inhibiting Gbg signaling
and its interaction with GRK2 and PI3Kg could be of ther-
apeutic value in HF (5,16,29,30). This has been demonstrated
by large peptide inhibitors of Gbg binding in both cell culture
and animal models of HF (2,6,14–17,31). In our study, small
molecule Gbg inhibition by gallein reduced GRK2 expression
and GRK2–PI3K110g membrane recruitment, thus preser-
ving b-AR membrane expression and cardiac function.
Gallein interrupts activation of the cardiac Akt-GSK-3b
hypertrophic pathway. In addition to forming a complex
with GRK2 that desensitizes b-AR, PI3Kg is of speciﬁc
interest in HF because it mediates a myriad of pathological
effects. PI3Kg activates Akt/PKB after GPCR activation,
leading to pathological hypertrophy (28,32,33). Conversely,
loss or reduction of activity is associated with increased
contractility, relaxation, and reduced hypertrophy (34). Akt
is a well-known player in cardiac hypertrophy with a large
number of downstream effectors. In particular, phosphory-
lated Akt mediates GSK-3b Ser-9 phosphorylation, thus
inhibiting its antihypertrophic effects. Our results suggest that
attenuated Akt activation in gallein-treated TAC mice results
in elevated levels of active (nonphosphorylated) GSK-3b
that attenuates cardiac hypertrophy by negatively regulating
hypertrophic gene transcription and protein translation (35).
Systemic gallein treatment normalizes sympathetic tone
and adrenal function in TAC mice. The adrenal glands,
speciﬁcally adrenal medullary chromafﬁn cells, are the site of CA
synthesis and secretion into the circulation. Adrenal chro-
mafﬁn cell a2-AR plays a crucial role in feedback regulation
of circulating levels of plasma CA (Fig. 7). Recent reports
demonstrate that HF prognosis is worse in patients with an
a2-AR deletion polymorphism that impairs feedback inhibi-
tion of CA release (36,37). Further, recent data demonstrate
that in HF, adrenal a2-AR are also desensitized by patho-
logical Gbg–GRK2 signaling (18,19), and that this desen-
sitization can possibly be mitigated by adrenal bARKct (38).
In our study, the salutary extracardiac effects of systemic
Gbg inhibition by gallein in chronic murine HF includedreduced plasma CA levels, limited adrenal medullary
hypertrophy, normalized adrenal a2-AR function, and
attenuated expression of both tyrosine hydroxylase, the rate-
limiting enzyme in CA synthesis, and chromogranin A,
a neurokine that is synthesized, costored, and cosecreted
with CA in chromafﬁn cell vesicles. To investigate whether
these adrenal effects resulted directly from gallein treatment
or were merely the result of HF amelioration, we examined
the direct effects of gallein treatment in ex vivo cultured
adrenal glands isolated from vehicle-treated isoproterenol-
pump HF mice, where gallein treatment directly restored
adrenal a2-AR function (Online Fig. 4).
Small molecule Gbg inhibition directly reduces CA
secretion in ex vivo cultured human pheochromocytoma.
To further investigate the salutary effect of gallein on CA
secretion in adrenal chromafﬁn cells, we utilized ex vivo
cultured human pheochromocytoma explants. Pheochro-
mocytoma is a CA-secreting tumor of the adrenal medulla
that is accompanied by cardiovascular complications (24).
Importantly, gallein treatment reduced CA secretion and
attenuated GRK2 expression and membrane translocation in
ex vivo pheochromocytoma culture with attenuated protein
expression of tyrosine hydroxylase and chromogranin A,
suggesting a direct inhibitory effect on CA synthesis and
secretion by chromafﬁn cells.
To date, pharmacological management of pheochromocy-
toma is poor at best, and surgical resection remains the ﬁnal
option. Our results suggest a possible therapeutic role for small
molecule Gbg inhibition in pheochromocytoma through its
direct effect on CA secretory mechanisms. Importantly, these
experiments were conducted immediately on explanted pheo-
chromocytomas obtained from human subjects.
Study limitations. The current study suggests therapeutic
beneﬁt of small molecule Gbg inhibition in an animal
model of HF, including salutary effects on adrenal cate-
cholamine secretion. Further studies in larger animal models
will be required to demonstrate therapeutic effects of this
novel agent to enable its progression toward clinical studies
for both pheochromocytoma and HF.
Conclusions
Recent reports have suggested that, if it were possible, sys-
temic pharmacological therapy to simultaneously normalize
pathological Gbg–GRK2 signaling in both the heart and
the adrenal gland could be of substantial therapeutic beneﬁt
in HF. Our present study suggests gallein to be such a
systemic pharmacological therapy. Administration of gallein
to animals after the establishment of HF in a clinically
relevant surgical model appears to normalize dampened AR
signaling in both the heart and the adrenal gland. Our data
also suggest a possible therapeutic role for small molecule
Gbg inhibition in other diseases of elevated catecholamine
release, such as pheochromocytoma. Future studies will seek
to further establish the therapeutic efﬁcacy of gallein in
larger animal models of HF.
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APPENDIX
For an expanded Methods section and supplemental ﬁgures, please see the
online version of this article.
